Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wells Fargo Maintains Overweight on Cabaletta Bio, Raises Price Target to $35

Author: Benzinga Newsdesk | March 22, 2024 01:40pm
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $34 to $35.

Posted In: CABA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist